scholarly journals Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy

2020 ◽  
Vol Volume 15 ◽  
pp. 2207-2215
Author(s):  
Chad Moretz ◽  
Ashley L Cole ◽  
George Mu ◽  
Benjamin Wu ◽  
Amy Guisinger ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Maintenance Therapy ◽  
Rescue Medication ◽  
Medication Use

scholarly journals Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol

2019 ◽  
Vol Volume 14 ◽  
pp. 2047-2060 ◽  
Author(s):  
Chad Moretz ◽  
Lindsay GS Bengtson ◽  
Lucie Sharpsten ◽  
Eleena Koep ◽  
Lisa Le ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Rescue Medication ◽  
Medication Use ◽  
Tiotropium Bromide

scholarly journals Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial

2020 ◽  
Vol 14 ◽  
pp. 175346662092694
Author(s):  
Edward M Kerwin ◽  
Isabelle H Boucot ◽  
Claus F Vogelmeier ◽  
Francois Maltais ◽  
Ian P Naya ◽  
...  
Keyword(s):  
Rescue Medication ◽  
Controlled Trial ◽  
Medication Use ◽  
Symptom Improvement ◽  
Chronic Obstructive ◽  
Electronic Diary ◽  
Double Blind ◽  
Clinical Trial Registration ◽  
Bronchodilator Therapy ◽  
Post Hoc

Background: In chronic obstructive pulmonary disease (COPD), both the time needed for patients to gain symptom improvement with long-acting bronchodilator therapy and whether an early response is predictive of a sustained response is unknown. This study aimed to investigate how quickly meaningful symptom responses are seen in patients with COPD with bronchodilator therapy and whether these responses are sustained. Methods: Early MAXimisation of bronchodilation for improving COPD stability (EMAX) was a 24-week, double-blind, double-dummy, parallel-group trial that randomised patients to umeclidinium/vilanterol (UMEC/VI), umeclidinium or salmeterol. Daily Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score and rescue salbutamol use were captured via an electronic diary and analysed initially in 4-weekly periods. Post hoc analyses assessed change from baseline in daily E-RS:COPD score and rescue medication use weekly (Weeks 1–8), and association between E-RS:COPD responder status at Weeks 1–4 and later time points. Results: In the intent-to-treat population ( n = 2425), reductions from baseline in E-RS:COPD scores and rescue medication use were apparent from Day 2 with all treatments. Treatment differences for UMEC/VI versus either monotherapy plateaued by Week 4–8 and were sustained at Weeks 21–24; improvements were consistently greater with UMEC/VI. For all treatments, most patients (60–85%) retained their Weeks 1–4 E-RS:COPD responder/non-responder status at Weeks 21−24. Among patients receiving UMEC/VI who were E-RS:COPD responders at Weeks 1–4, 70% were responders at Weeks 21–24. Conclusion: Patients with symptomatic COPD had greater potential for early symptom improvements with UMEC/VI versus either monotherapy. This benefit was generally maintained for 24 weeks. Early monitoring of treatment response can provide clinicians with an early indication of a patient’s likely longer-term response to prescribed bronchodilator treatment and will facilitate appropriate early adjustments in care. Clinical Trial Registration: NCT03034915, 2016-002513-22 (EudraCT Number). The reviews of this paper are available via the supplemental material section.

scholarly journals Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Yogesh Suresh Punekar ◽  
Sheetal Sharma ◽  
Ankit Pahwa ◽  
Jitender Takyar ◽  
Ian Naya ◽  
...  
Keyword(s):  
Systematic Review ◽  
Regression Analysis ◽  
Rescue Medication ◽  
Medication Use ◽  
Patient Reported Outcome ◽  
Patient Reported
Sign in / Sign up

Export Citation Format

Share Document